Project Description

Insulin-semi-long SMC

(injection suspension 100 units/ml) – Insulinum-semilongum SMC

international nonproprietary name

Insulin zinc suspension.



Pharmacotherapeutic group

Hormonal agent. Insulins.

Composition of the preparation

1 ml of the suspension contains 100 units of multi component of pork insulin. Insulin –semi-long SMC is a drug based on MC (multi component) pork insulin of high degree of purification, containing NMT 10 ppm of proinsulin.

Pharmacological action


Insulin-semi-long is of sugar decreasing action; it regulates carbohydrate metabolism, enhances glucose salvage and favors its transformation in glycogen.

The effect is revealed in 1-2 h. After injection; max.effect in 3-8 h., the duration is 10-16 h.


Absorption and initial effect depends on dose and volume of injection, concentration of insulin in a drug. Increased dose prolongs the effect. It is distributed irregularly between tissues. Diaplacental penetration of insulin is of no practical use due to rapid inactivation in placenta. It is mainly broken in liver (40-50% of the injected drug) and in kidneys (30% of the injected drug). Less than 1.5% of insulin is excreted unmodified.


Insulin-semi-long SMC is administered for diabetes and diseases of insulin-therapy.

special indication

Влияние на способность к вождению автотранспорта и управлению механизмами.

В связи с первичным назначением инсулина, сменой его вида или при наличии значительных физических или психических стрессов, возможно снижение способности к вождению автомобиля или к управлению различными механизмами, а также занятиям другими потенциально опасными видами деятельности, требующими повышенного внимания и быстроты психических и двигательных реакций.

special warning

Not established

Dosage and method of administration


Shake gently the vial with suspension before usage to mix the content evenly.

Take insulin from the vial boring the rubber cap preliminary cleaned with alcohol or iodide solution, with sterile needle of the syringe. The temperature of insulin for injection is ambient, change the place of introduction.

Doses are determined individually subject to general state of the solution of the patient, degree of severity and characteristics of the disease and daily glucose level and glycemic profile.

Usual daily dose of insulin-semi-long SMC is 0.5 — 1 U/kg of the body weigh.


Symptoms: hypoglycemia of various severity degree, hypoglycemic coma.

Treatment: in light hypoglycemia oral intake of glucose, in acute conditions i.v. stream injection (up to 50 ml of 40% solution) with concurrent introduction of glycagon or adrenaline.

safety measures

Administerthedrugwithcare. Overdose of the drug and undue intake of carbohydrates may cause hypoglycemia and hypoglycemic coma. Insulin may provoke allergic reaction of local and general nature. Administer this type of insulin if skin test is negative. In case of allergic reactions change insulin type and administer antiallergic therapy.

Follow safety measures in patients with coronary insufficiency or stroke, avoid overdoses.

Side effects

Conditioned carbohydrate metabolism: hypoglycemia. Allergicreactions: skineruption. Local reactions: lipodystrophy in place of injection (in long treatment). Other: transient vision disorder (usually at th beginning of therapy).


Hypoglycemia. Individual hypersensitivity to insulin or any of its components.

Interactions with other medicinal preparations

Some drugs influence insulin demand.

Antihyperglycemic action of insulin-semi-long SMC is enhanced by inhibitors МАО, non-selective beta-adrenergic blockers, sulphanilamides, anabolitic steroids, tetraciclyne, clophibrat, cyclophosphamide, phenphluramin, ethanol-preparations. Antihyperglycemic action of the drug is decreased by oral contraceptives, glycocorticoids, thyroid hormones, thiazide(-type) diuretic, heparin, lithium preparations, tricyclic antidepressants. Under reserpin and salicylate drug effect either decreased or increased.

The form of release

Injection suspension 100 units/ml in vial 10 ml.